Summit Therapeutics Inc. (SMMT) has a negative trailing P/E of -13.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 39.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -7.48%, forward earnings yield 2.52%. PEG 0.16 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -22.6 | -7.67 | -146.66 | 177.88 | - |
| 2018 | -22.0 | 1.93 | 63.70 | 44.40 | - |
| 2019 | 8.0 | -0.06 | 1.57 | 1.53 | - |
| 2019 | -1.7 | 0.00 | 0.65 | 62.47 | - |
| 2020 | -6.2 | -1.51 | 4.11 | 379.96 | - |
| 2021 | -2.8 | -0.11 | 2.98 | 137.16 | - |
| 2022 | -10.4 | 0.18 | 6.49 | 1,166.67 | - |
| 2023 | -2.6 | -0.02 | 20.82 | 0.00 | - |
| 2024 | -58.0 | 0.84 | 32.99 | 0.00 | - |
| 2025 | -12.1 | -0.03 | 19.85 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.43 | $2.88M | $-21.37M | -742% |
| 2017 | $-0.15 | $17.5M | $-28.53M | -163.1% |
| 2018 | $0.11 | $56.41M | $9.87M | 17.5% |
| 2019 | $-0.15 | $611.87K | $-23.88M | -3903.4% |
| 2020 | $-0.76 | $860K | $-52.7M | -6127.6% |
| 2021 | $-0.96 | $1.81M | $-88.6M | -4897.8% |
| 2022 | $-0.38 | $704.3K | $-78.78M | -11185.9% |
| 2023 | $-0.99 | $0.00 | $-614.93M | - |
| 2024 | $-0.31 | $0.00 | $-221.32M | - |
| 2025 | $-1.44 | $0.00 | $-1.08B | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.16 | $-1.19 – $-1.10 | $8.57M | $2.21M – $14.93M | 7 |
| 2027 | $-1.16 | $-1.19 – $-1.12 | $108.31M | $72.41M – $144.22M | 5 |
| 2028 | $-0.25 | $-2.04 – $2.75 | $936.39M | $592.85M – $1.28B | 6 |
| 2029 | $0.65 | $0.34 – $0.96 | $2.51B | $1.59B – $3.43B | 4 |
| 2030 | $1.89 | $0.99 – $2.80 | $4.44B | $2.81B – $6.07B | 2 |
